Member Info for icepick

Topped up 18k

Now NT

GLA

Been slowly building a position here.

Now at 800k.

Might be able to manage one more 200k top up before the pop, which can't be too far away.

Happy to be holding

GLA

2M top up for me

Averaged down

Still underwater but hopeful

GLA

120k top up for me

GLA

Topped up 100k @ 1.8

climbing again now

GLA

Having top sliced @ 2.66 last week, I have put in a cheeky fill or kill for 100k @ 1.65

Not expecting it, but you never know.

GLA

Filtered

Filtered

I've been building a bio tech portfolio over the last quarter.

Nice rise today for CLBX

Makes my portfolio look good.

Another you may like to look at CIZ

GLA

Just topped up 12.5k

Would be nice to get back to 50s

GLA

Topped up this morning with another 200k

GLA

*ramper

I've just filtered the tamper

GLA

B-positive

Do us and yourself a favour and stop the repeat posting the

It serves no purpose

Plans are laid out on their website.

Once excessive rainwater has reversed they will resume in short order.

An update sometime this month will be most welcome.

Happy to be holding.

GLA

Still very much under the radar.

GLA

Explorers seldom become producers.

Timescales and costs are usually prohibitive for explorers.

Normally resource proved to JORC and than sold on or farmed out.

Enjoy the ride

GLA

I have top sliced this pm.

Still holding a shed load @ 1.2 average.

Put some profit into CDL

GLA

Currently well under the radar.

EpiSwitch Prostate Screening (PSE), developed by Oxford BioDynamics, is considered a highly promising technology for the UK National Health Service (NHS), but it is not yet subscribed to or part of standard NHS care.

The Focal Therapy Clinic

As of late 2025, while not currently mandated, it is highly likely that the NHS will consider adopting it due to recent evidence and high-level recommendations.

Here is an analysis of its likelihood of adoption:

High Likelihood Factors (The Case for Adoption)

Superior Accuracy: EpiSwitch PSE boosts prostate cancer detection accuracy to 94% (compared to 55% for the standard PSA test) and has an unmatched 97% specificity, which is ideal for reducing false positives.

Reduced Costs and Biopsies: A 2025 Prostate Cancer Research (PCR) report concluded that implementing the PSE test could reduce unnecessary MRIs by over 86% and biopsies by 84%. This offers substantial cost savings to the NHS, creating a strong economic case for adoption.

UK Provenance: It was developed through a ten-year collaboration involving Imperial College, Imperial NHS Trust, and the University of East Anglia, making it a "homegrown" technology.

Growing Endorsement: Recent 2025 reporting suggests the PSE test should be "considered in the NHS" and that it is "feasible and effective" to reduce inequalities and save lives.

Available Privately: It is currently available privately in the UK, including at Imperial Private Healthcare.

Imperial College Healthcare Private Care

Barriers to Immediate NHS Adoption

Need for Further Evidence: While studies are strong, they are relatively small, and leading charities like Prostate Cancer UK have suggested more research is needed for large-scale, routine use.

National Screening Committee Approval: Extending it to the general public depends on the NHS National Screening Committee reviewing the test for official screening protocols, a process that takes time.

NICE Approval: It is not yet recommended by NICE (National Institute for Health and Care Excellence), which is typically required for broad NHS adoption.

The Focal Therapy Clinic

Summary: EpiSwitch PSE is currently the strongest candidate for upgrading prostate diagnostics in the UK. Given the mounting evidence of its cost-saving potential and high accuracy, its adoption as a "reflex test" (a follow-up test after an initial high PSA result) is highly likely in the coming years.